The widespread use of adjuvant therapy, mainly anthracyclines, over the last 10 years is effective for recurrence in patients with early breast cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1620, 2008-01, pp. : 2-2

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardioprotective Effect of Dexrazoxane in Patients with Breast Cancer Treated with Anthracyclines in Adjuvant Setting: A 10-Year Single Institution Experience

By Testore Franco   Milanese Simona   Ceste Marco   Enrico de Conciliis   Parello Giuseppe   Lanfranco Claudio   Manfredi Roberto   Ferrero Gianfranco   Simoni Carlotta   Miglietta Loredana   Ferro Silvia   Giaretto Lorena   Bosso Giuseppina  

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 4, 2008-01 ,pp. : 257-263

Adis International

Access to resources Recommend Favorite

Paclitaxel: As Adjuvant or Neoadjuvant Therapy in Early Breast Cancer

By Dene Simpson   Greg L. Plosker  

Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. : 1839-1847

Adis International

Access to resources Recommend Favorite

Breast cancer adjuvant therapy use increases in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 367, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Use of LHRH-agonists as adjuvant therapy for breast cancer

By Cuzick Jack  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 8, 2008-08 ,pp. : 1065-1071

Informa Healthcare

Access to resources Recommend Favorite

Adjuvant hormonal therapy use appears to be low among insured, low-income woman with early breast cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 582, 2009-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite